Integrating computational and chemical biology tools in the discovery of antiangiogenic small molecule ligands of FGF2 derived from endogenous inhibitors

Chiara Foglieni, Katiuscia Pagano, Marco Lessi, Antonella Bugatti, Elisabetta Moroni, Denise Pinessi, Andrea Resovi, Domenico Ribatti, Sabrina Bertini, Laura Ragona, Fabio Bellina, Marco Rusnati, Giorgio Colombo, Giulia Taraboletti

Research output: Contribution to journalArticle

Abstract

The FGFs/FGFRs system is a recognized actionable target for therapeutic approaches aimed at inhibiting tumor growth, angiogenesis, metastasis, and resistance to therapy. We previously identified a non-peptidic compound (SM27) that retains the structural and functional properties of the FGF2-binding sequence of thrombospondin-1 (TSP-1), a major endogenous inhibitor of angiogenesis. Here we identified new small molecule inhibitors of FGF2 based on the initial lead. A similarity-based screening of small molecule libraries, followed by docking calculations and experimental studies, allowed selecting 7 bi-naphthalenic compounds that bound FGF2 inhibiting its binding to both heparan sulfate proteoglycans and FGFR-1. The compounds inhibit FGF2 activity in in vitro and ex vivo models of angiogenesis, with improved potency over SM27. Comparative analysis of the selected hits, complemented by NMR and biochemical analysis of 4 newly synthesized functionalized phenylamino-substituted naphthalenes, allowed identifying the minimal stereochemical requirements to improve the design of naphthalene sulfonates as FGF2 inhibitors.

Original languageEnglish
Article number23432
JournalScientific Reports
Volume6
DOIs
Publication statusPublished - Mar 22 2016

Fingerprint

Fibroblast Growth Factor 2
Ligands
Molecules
Naphthalenes
Thrombospondin 1
Heparan Sulfate Proteoglycans
Angiogenesis Inhibitors
Tumors
Screening
Nuclear magnetic resonance

ASJC Scopus subject areas

  • General

Cite this

Integrating computational and chemical biology tools in the discovery of antiangiogenic small molecule ligands of FGF2 derived from endogenous inhibitors. / Foglieni, Chiara; Pagano, Katiuscia; Lessi, Marco; Bugatti, Antonella; Moroni, Elisabetta; Pinessi, Denise; Resovi, Andrea; Ribatti, Domenico; Bertini, Sabrina; Ragona, Laura; Bellina, Fabio; Rusnati, Marco; Colombo, Giorgio; Taraboletti, Giulia.

In: Scientific Reports, Vol. 6, 23432, 22.03.2016.

Research output: Contribution to journalArticle

Foglieni, C, Pagano, K, Lessi, M, Bugatti, A, Moroni, E, Pinessi, D, Resovi, A, Ribatti, D, Bertini, S, Ragona, L, Bellina, F, Rusnati, M, Colombo, G & Taraboletti, G 2016, 'Integrating computational and chemical biology tools in the discovery of antiangiogenic small molecule ligands of FGF2 derived from endogenous inhibitors', Scientific Reports, vol. 6, 23432. https://doi.org/10.1038/srep23432
Foglieni, Chiara ; Pagano, Katiuscia ; Lessi, Marco ; Bugatti, Antonella ; Moroni, Elisabetta ; Pinessi, Denise ; Resovi, Andrea ; Ribatti, Domenico ; Bertini, Sabrina ; Ragona, Laura ; Bellina, Fabio ; Rusnati, Marco ; Colombo, Giorgio ; Taraboletti, Giulia. / Integrating computational and chemical biology tools in the discovery of antiangiogenic small molecule ligands of FGF2 derived from endogenous inhibitors. In: Scientific Reports. 2016 ; Vol. 6.
@article{bb3926fae56a41b5ad13dc3269bc1020,
title = "Integrating computational and chemical biology tools in the discovery of antiangiogenic small molecule ligands of FGF2 derived from endogenous inhibitors",
abstract = "The FGFs/FGFRs system is a recognized actionable target for therapeutic approaches aimed at inhibiting tumor growth, angiogenesis, metastasis, and resistance to therapy. We previously identified a non-peptidic compound (SM27) that retains the structural and functional properties of the FGF2-binding sequence of thrombospondin-1 (TSP-1), a major endogenous inhibitor of angiogenesis. Here we identified new small molecule inhibitors of FGF2 based on the initial lead. A similarity-based screening of small molecule libraries, followed by docking calculations and experimental studies, allowed selecting 7 bi-naphthalenic compounds that bound FGF2 inhibiting its binding to both heparan sulfate proteoglycans and FGFR-1. The compounds inhibit FGF2 activity in in vitro and ex vivo models of angiogenesis, with improved potency over SM27. Comparative analysis of the selected hits, complemented by NMR and biochemical analysis of 4 newly synthesized functionalized phenylamino-substituted naphthalenes, allowed identifying the minimal stereochemical requirements to improve the design of naphthalene sulfonates as FGF2 inhibitors.",
author = "Chiara Foglieni and Katiuscia Pagano and Marco Lessi and Antonella Bugatti and Elisabetta Moroni and Denise Pinessi and Andrea Resovi and Domenico Ribatti and Sabrina Bertini and Laura Ragona and Fabio Bellina and Marco Rusnati and Giorgio Colombo and Giulia Taraboletti",
year = "2016",
month = "3",
day = "22",
doi = "10.1038/srep23432",
language = "English",
volume = "6",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Integrating computational and chemical biology tools in the discovery of antiangiogenic small molecule ligands of FGF2 derived from endogenous inhibitors

AU - Foglieni, Chiara

AU - Pagano, Katiuscia

AU - Lessi, Marco

AU - Bugatti, Antonella

AU - Moroni, Elisabetta

AU - Pinessi, Denise

AU - Resovi, Andrea

AU - Ribatti, Domenico

AU - Bertini, Sabrina

AU - Ragona, Laura

AU - Bellina, Fabio

AU - Rusnati, Marco

AU - Colombo, Giorgio

AU - Taraboletti, Giulia

PY - 2016/3/22

Y1 - 2016/3/22

N2 - The FGFs/FGFRs system is a recognized actionable target for therapeutic approaches aimed at inhibiting tumor growth, angiogenesis, metastasis, and resistance to therapy. We previously identified a non-peptidic compound (SM27) that retains the structural and functional properties of the FGF2-binding sequence of thrombospondin-1 (TSP-1), a major endogenous inhibitor of angiogenesis. Here we identified new small molecule inhibitors of FGF2 based on the initial lead. A similarity-based screening of small molecule libraries, followed by docking calculations and experimental studies, allowed selecting 7 bi-naphthalenic compounds that bound FGF2 inhibiting its binding to both heparan sulfate proteoglycans and FGFR-1. The compounds inhibit FGF2 activity in in vitro and ex vivo models of angiogenesis, with improved potency over SM27. Comparative analysis of the selected hits, complemented by NMR and biochemical analysis of 4 newly synthesized functionalized phenylamino-substituted naphthalenes, allowed identifying the minimal stereochemical requirements to improve the design of naphthalene sulfonates as FGF2 inhibitors.

AB - The FGFs/FGFRs system is a recognized actionable target for therapeutic approaches aimed at inhibiting tumor growth, angiogenesis, metastasis, and resistance to therapy. We previously identified a non-peptidic compound (SM27) that retains the structural and functional properties of the FGF2-binding sequence of thrombospondin-1 (TSP-1), a major endogenous inhibitor of angiogenesis. Here we identified new small molecule inhibitors of FGF2 based on the initial lead. A similarity-based screening of small molecule libraries, followed by docking calculations and experimental studies, allowed selecting 7 bi-naphthalenic compounds that bound FGF2 inhibiting its binding to both heparan sulfate proteoglycans and FGFR-1. The compounds inhibit FGF2 activity in in vitro and ex vivo models of angiogenesis, with improved potency over SM27. Comparative analysis of the selected hits, complemented by NMR and biochemical analysis of 4 newly synthesized functionalized phenylamino-substituted naphthalenes, allowed identifying the minimal stereochemical requirements to improve the design of naphthalene sulfonates as FGF2 inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=84961603843&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961603843&partnerID=8YFLogxK

U2 - 10.1038/srep23432

DO - 10.1038/srep23432

M3 - Article

VL - 6

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 23432

ER -